Stock BIOV BIOVAXYS TECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 01:54:18 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.075 CAD 0.00% Intraday chart for BioVaxys Technology Corp. -6.25% +50.00%
Apr. 10 Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry CI
Apr. 03 BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage CI

Valuation

Fiscal Period: Oktober 2020 2021 2022
Capitalization 1 29.91 34.11 22.31
Enterprise Value (EV) 1 27.48 33.52 22.16
P/E ratio -10.1 x -4.75 x -1.72 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF -452,322,377 x -12,388,775 x -30,122,929 x
FCF Yield -0% -0% -0%
Price to Book 3.25 x 4.17 x -28.8 x
Nbr of stocks (in thousands) 71,203 92,187 108,813
Reference price 2 0.4200 0.3700 0.2050
Announcement Date 3/1/21 2/28/22 3/3/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Oktober 2019 2020 2021 2022
Net sales - - - -
EBITDA - - - -
EBIT 1 -0.1833 -1.009 -5.979 -3.803
Operating Margin - - - -
Earnings before Tax (EBT) 1 -0.2169 -1.103 -6.458 -11.73
Net income 1 -0.2301 -1.174 -6.458 -11.73
Net margin - - - -
EPS 2 -0.0222 -0.0416 -0.0779 -0.1194
Free Cash Flow - -0.0608 -2.705 -0.7358
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 3/1/21 3/1/21 2/28/22 3/3/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: Oktober 2019 2020 2021 2022
Net Debt 1 - - - -
Net Cash position 1 0.23 2.42 0.59 0.14
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -0.06 -2.71 -0.74
ROE (net income / shareholders' equity) - -22.6% -72.8% -317%
ROA (Net income/ Total Assets) - -11.7% -39.4% -50.7%
Assets 1 - 10.02 16.38 23.11
Book Value Per Share 2 0.0200 0.1300 0.0900 -0.0100
Cash Flow per Share 2 0.0200 0.0300 0.0100 0
Capex - - - -
Capex / Sales - - - -
Announcement Date 3/1/21 3/1/21 2/28/22 3/3/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOVAXYS TECHNOLOGY CORP. Stock BioVaxys Technology Corp.
+50.00% 11.55M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.57% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-15.51% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.74% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.33% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.15% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOV Stock
  4. Financials BioVaxys Technology Corp.